2026-01-10 - Analysis Report
Here's a comprehensive analysis of Eli Lilly (LLY) based on the provided data:

**0) Overview**

*   **LLY: Eli Lilly and Co.** is a global pharmaceutical company.

**1) Return Rate Comparison**

*   **LLY Cumulative Return:** 283.38%
*   **VOO (S&P 500) Cumulative Return:** 92.74%
*   **Divergence:** 190.7 (Relative Divergence: 83.9)

**Analysis:**

LLY has significantly outperformed the S&P 500 (VOO) over the tracked period, with a large divergence in cumulative returns. The relative divergence of 83.9 suggests the current outperformance is positioned high within its historical range, indicating strong recent momentum.

**Alpha, Beta Analysis:**

| Year      | CAGR   | MDD   | Alpha  | Beta | Cap(B) |
| --------- | ------ | ----- | ------ | ---- | ------ |
| 2016-2018 | 37.0%  | 14.3% | 33.0%  | 0.7  | 101.7  |
| 2017-2019 | 36.0%  | 14.7% | 19.0%  | 0.7  | 115.5  |
| 2018-2020 | 30.0%  | 20.9% | 10.0%  | 0.7  | 148.3  |
| 2019-2021 | 49.0%  | 20.9% | 5.0%   | 0.7  | 242.7  |
| 2020-2022 | 59.0%  | 20.9% | 60.0%  | 0.7  | 321.4  |
| 2021-2023 | 116.0% | 18.0% | 115.0% | 0.5  | 512.1  |
| 2022-2024 | 123.0% | 27.0% | 104.0% | 0.6  | 678.3  |
| 2023-2025 | 183.0% | 29.9% | 121.0% | 0.7  | 944.2  |

**Analysis:**

*   **CAGR:**  Shows consistently high compounded annual growth rates, particularly accelerating in recent periods (2021-2025).
*   **MDD:** Maximum Drawdown indicates the largest peak-to-trough decline during each period. Drawdown has increased in recent years.
*   **Alpha:** LLY consistently generates significant alpha, indicating outperformance relative to its benchmark (risk-adjusted return). Alpha has recently increased.
*   **Beta:**  The beta is consistently below 1 (around 0.7), suggesting that LLY is less volatile than the market (S&P 500).
*   **Cap(B):** Market capitalization has grown dramatically, reflecting its growth and outperformance.

**2) Recent Stock Price Fluctuations**

*   **Close:** 1085.19
*   **Last-market:** Price: 1063.56, Previous Close: 1085.19, Change: -1.99%
*   **5-day SMA:** 1075.84
*   **20-day SMA:** 1061.62
*   **60-day SMA:** 984.12

**Analysis:**

*   The stock price is trading below its previous close and its 5-day SMA, but above its 20-day and 60-day SMAs. This suggests a short-term pullback within a longer-term uptrend.  The large drop in the Last-market indicates fluctuation issues (sharp decline).

**3) Indicators**

*   **MRI:** 0.7 (Medium Investment)
*   **RSI:** 61.62
*   **PPO:** -0.18
*   **Hybrid Signal:** Buy 100% (Very Safe)
*   **Recent Divergence Change:** 0.6 (+): Short-term increase.
*   **Expected Return:** 47.3%

**Analysis:**

*   **MRI:** A medium investment recommendation suggests a moderate level of risk and potential reward.
*   **RSI:** An RSI of 61.62 is close to being overbought (above 70), suggesting the stock could be due for a correction.
*   **PPO:** A slightly negative PPO indicates the short-term moving average is slightly below the long-term moving average, confirming the short-term pullback observed from the SMAs.
*   **Hybrid Signal:** The "Buy 100%" signal suggests a strong positive outlook based on the model's algorithms.
*   **Recent Divergence Change:** Recent increase in short-term divergence suggests a recent increase
*   **Expected Return:** The high expected return suggests continued positive performance.

**4) Recent News & Significant Events**

*   **Acquisition:** Eli Lilly buys Ventyx Biosciences for $1.2 Billion (Expansion/Growth)
*   **Treatment Focus:** Eli Lilly bets $1.2B on pill-based treatments for chronic inflammation. (R&D/Pipeline)
*   **Positive Outlook:** Articles highlight LLY's fundamentals, undervaluation, and momentum. (Bullish Sentiment)
*   **Potential Risk:** Warning about a hidden risk with the stock's rise. (Cautionary)

**Analysis:**

The news indicates both positive momentum and potential risks. The acquisition and treatment focus demonstrate the company's investment in future growth, while the warning about a hidden risk suggests the need for caution and further due diligence.

**4-2) Analyst Opinions:**

*   **Consensus:** Buy (Mean: 1.70)
*   **Target Price:** Average: 1116.33, High: 1500.00, Low: 770.00

**Analysis:**

Analysts generally have a positive outlook on LLY, with a "Buy" consensus and an average target price higher than the current price. The wide range in target prices indicates some uncertainty among analysts.

**5) Recent Earnings Analysis**

| Date       | EPS  | Revenue     |
| ---------- | ---- | ----------- |
| 2025-10-30 | 6.22 | 17.60 B$    |
| 2025-08-07 | 6.30 | 15.56 B$    |
| 2025-05-01 | 3.07 | 12.73 B$    |
| 2024-10-30 | 1.08 | 11.44 B$    |
| 2025-10-30 | 1.08 | 11.44 B$    |

**Analysis:**

*   EPS (Earnings Per Share) shows a notable increase, especially in the most recent quarters.
*   Revenue has also been consistently increasing, indicating strong growth in sales.

**6) Financial Information: Revenue, Profitability, Capital and Profitability**

**Revenue and Profitability:**

| Quarter      | Revenue     | Profit Margin |
| ------------ | ----------- | ------------- |
| 2025-09-30   | $17.60B    | 82.91%        |
| 2025-06-30   | $15.56B    | 84.27%        |
| 2025-03-31   | $12.73B    | 82.53%        |
| 2024-12-31   | $13.53B    | 82.24%        |
| 2024-09-30   | $11.44B    | 81.02%        |

**Capital and Profitability:**

| Quarter      | Equity      | ROE    |
| ------------ | ----------- | ------- |
| 2025-09-30   | $23.79B    | 23.46%  |
| 2025-06-30   | $18.27B    | 30.98%  |
| 2025-03-31   | $15.76B    | 17.50%  |
| 2024-12-31   | $14.19B    | 31.07%  |
| 2024-09-30   | $14.24B    | 6.81%   |

**Analysis:**

*   **Revenue:** Consistent and strong revenue growth over the past several quarters.
*   **Profit Margin:** Very high and stable profit margins, indicating efficiency and pricing power.
*   **Equity:** Growing equity base, reflecting retained earnings and overall financial health.
*   **ROE:** Generally high ROE (Return on Equity), but fluctuating, suggesting the company is effectively using shareholder equity to generate profits.

**7) Comprehensive Analysis**

Eli Lilly (LLY) exhibits a strong financial profile with high growth, profitability, and positive market sentiment.

*   **Strengths:**
    *   Exceptional historical outperformance (high cumulative return and alpha).
    *   Strong revenue and earnings growth.
    *   High and stable profit margins.
    *   Positive analyst consensus.
    *   Significant R&D investment in key areas.
*   **Weaknesses/Risks:**
    *   Short-term price pullback and slightly negative PPO signal possible consolidation.
    *   High RSI may indicate overbought conditions.
    *   News articles mentioning a "hidden risk" warrant further investigation.
    *   High valuation reflected in the significant divergence from the S&P 500.
    *   Fluctuating ROE suggests that profitability is not consistent
*   **Overall:**
    *   The company demonstrates substantial growth and market dominance, supported by strong financials and positive analyst sentiment.
    *   Investors should be aware of potential short-term volatility and the need for further research into the identified risks.
    *   The MRI's medium investment recommendation appears reasonable given the balance of positive and cautionary signals.



**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.